Mizuho initiated coverage on Climb Bio with a new price target
$CLYM
Biotechnology: Pharmaceutical Preparations
Health Care
Mizuho initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $18.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/8/2026 | $35.00 | Buy | Guggenheim |
| 5/5/2026 | $22.00 | Buy | Chardan Capital Markets |
| 4/15/2026 | $18.00 | Outperform | Mizuho |
| 3/24/2026 | $26.00 | Buy | B. Riley Securities |
| 3/18/2026 | $17.00 | Buy | Truist |
| 3/11/2026 | $25.00 | Strong Buy | Raymond James |
| 3/5/2026 | $12.00 | Outperform | Wedbush |
| 2/13/2026 | $23.00 | Overweight | Piper Sandler |
Guggenheim initiated coverage of Climb Bio with a rating of Buy and set a new price target of $35.00
Chardan Capital Markets initiated coverage of Climb Bio with a rating of Buy and set a new price target of $22.00
Mizuho initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $18.00
Data demonstrate favorable safety and tolerability profile, robust B-cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY HILLS, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced initial data from the ongoing Phase 1b portion of its Phase 1b/2a study evaluating budoprutug, an anti-CD19 monoclonal antibody, in adults with primary immune thrombocytopenia (ITP) demonstrating an enc
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. Clinical data demonstrated a favorable initial safety profile, supporting continued development of CLYM116 in IgA nephropathy (IgAN). These data will be pres
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026. Climb Bio will present pharmacokinetic/pharmacodynamic modeling from nonhuman primates to humans for CLYM116, a novel ‘sweeper' anti-APRIL monoclonal antibody, which is being developed to treat IgA nephropathy (IgAN). Initial safety data from the ongoing CLYM116 Phase 1 study in healthy volunteers will also be presen
8-K - Climb Bio, Inc. (0001768446) (Filer)
424B5 - Climb Bio, Inc. (0001768446) (Filer)
8-K - Climb Bio, Inc. (0001768446) (Filer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
4 - Climb Bio, Inc. (0001768446) (Issuer)
SC 13G/A - Climb Bio, Inc. (0001768446) (Subject)
WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has strengthened its leadership team with the addition of Susan Altschuller, Ph.D., MBA, as Chief Financial Officer. Susan brings over two decades of strategic and financial leadership experience. "Susan is a seasoned biopharmaceutical leader with a strong track record in financial strategy, capital allocation, and operational execution, and we are delighted to welcome her to our team," said Aoife Brennan, President and CEO of Climb Bio. "Our company is making excellent progress advanci
Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi
WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. "We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio," said Aoife Brennan, President and CEO of Climb Bio. "Kim and Bo each bring three decades of leadership experience in the biotechnology and pharmaceutical industry, offering invaluable perspective as we continue to build the company and advance our pipeline. Their insight